Joint sessions

Debate: Coronary Artery Calcification is Primary Prevention
Raul Santos, Brazil
Michael Shapiro, USA

How Early is too Early for ASCVD Prevention?
John William McEvoy, Ireland

Women and Risk Factors for ASCVD: Sex Specific Considerations
Jeanine Roeters Van Lennep, The Netherlands

A practical approach to effective smoking caseation
Giuseppe Biondi-Zoccai, Italy

Exercise in obese individuals with multiple co-morbidities; What works?
Martin Bahls, Germany

Applying risk scores in clinical practice; What scores for which patients?
Lisa Pennells, UK

Risk modifiers; How to incorporate them in CV prevention?
Maryam Kavousi, The Netherlands

How do TG levels vary in CAD patients across WHO regions
Peter Libby, USA

How do traditional lipids differ in CAD patients across WHO regions
Kausik Ray, UK

Measures of Glycaemia in CAD patients - How do they differ across regions
Lars Rydén, Sweden

Characteristics of patients with CAD across WHO regions
David Wood, Ireland

Disaggregating the lipid panel- why should I bother?
Christie Ballantyne, USA

Lp(a) who to measure and what to do about it?
Florian Kronenberg, Austria

To apoB or not to apoB
Daniel Soffer, USA

LDL-C lowering across the specrtum of dyslipidaemias- why it remains the primary target
Kausik Ray, UK